Whole-slide Image and CT Radiomics Based Deep Learning System for Prognostication Prediction in Upper Tract Urothelial Carcinoma

NCT ID: NCT06993779

Last Updated: 2025-05-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-01

Study Completion Date

2025-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Upper Tract Urothelial Carcinoma (UTUC), characterized by its anatomical complexity and often aggressive clinical behavior, presents substantial difficulties in accurate diagnosis and reliable prognostication. The stratification of postoperative survival utilizing radiomics features derived from imaging and characteristics from whole slide images could prove instrumental in guiding therapeutic decisions to enhance patient outcomes. In this research, our objective is to construct a deep learning-based prognostic-stratification system designed for the automated prediction of overall and cancer-specific survival in individuals diagnosed with UTUC.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Upper Tract Urothelial Carcinoma (UTUC) can be challenging to accurately diagnose and its course difficult to predict, as the disease manifestations and aggressiveness can differ significantly among individuals. This research seeks to create an innovative system employing artificial intelligence to process patient data, encompassing images from diagnostic scans and surgical pathology slides. This system would then be capable of automatically forecasting a patient's overall survival and their specific likelihood of surviving UTUC. Such insights could empower clinicians to tailor more effective treatment strategies for each individual patient.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

UTUC

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AI-UTUC

Patients with Upper Tract Urothelial Carcinoma (UTUC) who underwent radical nephroureterectomy (RNU)

Deep learning system for prognostication prediction in upper tract urothelial carcinoma

Intervention Type OTHER

develop and validate a deep learning system for prognostication prediction in upper tract urothelial carcinoma based on CT radiomics and whole slide images.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Deep learning system for prognostication prediction in upper tract urothelial carcinoma

develop and validate a deep learning system for prognostication prediction in upper tract urothelial carcinoma based on CT radiomics and whole slide images.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with Upper Tract Urothelial Carcinoma (UTUC) who had radical nephroureterectomy (RNU).
* Contrast-enhanced CT scan (e.g., CT urography) less than two weeks before surgery.
* Complete CT image data and clinical data.
* Complete whole slide image data.

Exclusion Criteria

* Patients with a postoperative diagnosis of non-urothelial carcinoma.
* Poor quality of CT images and/or whole slide image data.
* Incomplete clinical and follow-up data.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mingzhao Xiao

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mingzhao Xiao

Professor

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Urology, The First Affiliated Hospital of Chongqing Medical University, chongqing, chongqing 400016 Recruiting

Chongqing, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

K2024-187-07

Identifier Type: OTHER

Identifier Source: secondary_id

AI-UTUC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Radiomics in Rectal Cancer
NCT05331040 UNKNOWN